UK MHRA Opens Consultation on Draft Medical Device Regulations: Pre-Market Requirements for Devices and IVDs

News & Regulatory Updates

Date: 11 May 2026

Source: UK MHRA / GOV.UK

Original publication date: 2026-05-11

Site publication date: 2026-07-08 09:00

Original link: https://www.gov.uk/government/consultations/medical-devices-regulations-draft-pre-market-requirements

UK MHRA Opens Consultation on Draft Medical Device Regulations

On 11 May 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published a consultation on draft pre-market regulatory requirements for medical devices and in vitro diagnostic medical devices (IVDs) entering the UK market. The draft covers international regulatory recognition, unique device identification (UDI), implant cards, IVD classification, retention of technical documentation, and consistency of product claims.

Full Translated Core Content

The MHRA has issued a consultation on proposed amendments to medical device regulations, covering pre-market regulatory requirements for medical devices and IVDs entering the UK market. The draft focuses on international regulatory recognition, UDI, implant cards, IVD classification, retention of technical documentation, and consistency of product claims.

UK medical device regulation is gradually moving from transitional arrangements towards a more complete domestic regulatory system. Companies need to monitor the interfaces among UKCA marking, the CE transition period, the UK responsible person, MHRA registration, technical file retention, labeling, and post-market surveillance obligations.

For Chinese companies planning to enter the UK market, it is important to continue tracking the implementation timeline and final requirements of the draft, and to avoid arranging long-term market strategies solely on the basis of transitional policies.

AIMEILI Regulatory Interpretation

AIMEILI Regulatory Affairs Department considers that updates of this kind reflect a global regulatory shift from pre-market access towards life-cycle transparency management. UDI, EUDAMED, SSCP, adverse event terminology, and electronic reporting systems may appear to belong to different regulatory modules, but they point to a common requirement: after a product is placed on the market, it must be identifiable, traceable, updatable, and publicly explainable, and companies must be able to demonstrate ongoing compliance through structured data.

For companies, this is not a matter of a single label field or database account. It is an integrated engineering task linking registration dossiers, packaging and labels, ERP codes, distributor management, post-market surveillance (PMS) plans, complaint handling, recall processes, and certificate maintenance. If the model on the registration certificate, the identifier on the label, the product information in the database, the terminology used in post-market reports, and the distributor's actual sales scope are inconsistent, risks can arise during subsequent reviews, recalls, or certificate renewals.

AIMEILI recommends that companies establish a global product master data table as early as possible, covering at least product name, model and specification, intended use, risk class, certificate number, UDI/traceability code, label version, countries of sale, local responsible entity, and post-market reporting requirements. In markets such as the European Union, Australia, the United States, Canada, and Singapore, product data governance capability will increasingly affect companies' registration efficiency and ability to maintain continuous market supply.

Business Impact

This update may affect companies' assessment of registration pathways, technical file preparation, labels and instructions for use, quality system records, and post-market maintenance arrangements. Companies should conduct an internal assessment based on the target market, product risk class, existing certificates, and sales plans, rather than treating regulatory news as general information only.

Recommended Compliance Actions

• Confirm whether the update affects existing registration pathways, certificate maintenance, or post-market obligations.
• Verify technical documentation, labels and instructions for use, quality system, and local responsible entity arrangements in target countries.
• Establish change impact assessments and regulatory update tracking records for products already on the market.
• Where necessary, archive official source texts, translated interpretations, and internal action items for future audits and project reviews.

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI International Medical Device Registration Project Team

Source principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as supporting judgment.

Scope: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of target-country regulators, testing conclusions, or legal advice.